Dr. Paul Ridker, of Brigham and Women’s Hospital, Boston, discusses with Dr. Ron Waksman results from the RESCUE trial, which randomized patients at high atherosclerotic risk with stage 3-5 chronic kidney disease to receive ziltivekimab, a novel interleukin-6 ligand inhibitor (7.5 mg, 15 mg or 30 mg) or a placebo. The study, presented as a late-breaking trial at ACC.21 Virtual, found that ziltivekimab markedly reduced multiple biomarkers of systemic inflammation and thrombosis known to promote the atherosclerotic process as compared to placebo.